With this appointment, Coriolis strengthens its Board of Directors with additional global expertise from the service sector for the pharmaceutical and biotech industry.
MARTINSRIED-MUNICH, Germany, March 11, 2025 / Biotech Newswire / -- Coriolis Pharma, a global contract research and development organization (CRDO) and a leader in formulation research and development of biopharmaceuticals, including cell and gene therapy products and vaccines, has appointed Peter Sölkner as a non-executive director. The appointment underscores Coriolis’ commitment to strengthening its board of directors and driving its strategic growth objectives.
Peter Sölkner has more than 30 years of experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma, a global aseptic filling and packaging CDMO, where he has helped grow revenues more than fivefold over the past 15 years. Prior to Vetter, Mr. Sölkner held various senior positions at Sartorius including Vice President of the Americas region, where he expanded the global footprint of the business across the US and multiple sectors. He has an MBA from Columbia Business School, New York and Masters in Chemical Engineering from TU Dortmund University, Germany.
Dr. Michael Wiggenhorn, Founder and Board Member of Coriolis Pharma, commented: “On behalf of the Board, I am delighted to welcome Peter Sölkner as non-executive Director. His extensive experience in the pharma services industry will be a great asset to Coriolis Pharma. We look forward to his support and advice as we continue to drive the success of Coriolis.”
Peter Sölkner commented: “I look forward to support Coriolis in its continued growth and to enable its team of outstanding scientists and experts in their field to make further significant contributions to the development of life-changing therapies.”
“We warmly welcome Peter on board," said Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis. "Our focus on providing fully integrated services for pharmaceutical and biotech companies from preclinical to commercialization makes us a valuable partner not only for our clients but also for CDMOs. Peter’s expertise will be instrumental in guiding our strategic direction and ensuring continued success.”
The appointment of Peter Sölkner reflects Coriolis’ ongoing commitment to providing high-quality services and being an independent, reliable partner for CDMOs in jointly supporting the development of clients' products.
Caption: Peter Sölkner
For high resolution please click the image.
About Coriolis Pharma
Coriolis Pharma is a globally operating contract research and development organization (CRDO) and the premier partner for drug product development, analytical services and manufacturing services across a vast array of biological therapeutic modalities. With a focus on liquid and lyophilized drug products, Coriolis expert scientists design and execute platform and custom services to accelerate and derisk client programs right from the start and throughout the entire product lifecycle.
Headquartered in Martinsried near Munich, the company offers tailored solutions from early development stages to market approval. Coriolis Pharma stands out for its scientific excellence, innovative analytical methods, and deep understanding of formulation and drug product development.
Contact
Coriolis Pharma Research GmbH
Bettina von Klitzing-Stückle
Marketing Manager
+49 (0) 89 4177 60 – 0
This email address is being protected from spambots. You need JavaScript enabled to view it.
Fraunhoferstr. 18b
82152 Martinsried-Munich
Germany
www.coriolis-pharma.com
Keywords: Appointments and Schedules; Drug Delivery Systems; Drug Development; Drug Compounding; Laboratories; Genetic Therapy; Biological Products; Pharmaceutical Preparations; Biotechnology; Germany; Coriolis Pharma; Peter Sölkner; Board of Directors; pharmaceutical industry; biotech industry; contract research and development organization (CRDO); formulation research; biopharmaceuticals; cell and gene therapy; vaccines; strategic growth; CDMO (Contract Development and Manufacturing Organization); Vetter Pharma; aseptic filling; packaging; preclinical to commercialization; drug product development; analytical services; manufacturing services; liquid drug products; lyophilized drug products; Martinsried; Munich
Source: Biotech Newswire